

Open Innovation Drug Discovery (OIDD) Program Expansion and New Approaches for Collaboration

Dra. María Angeles Martínez-Grau
Senior Research Advisor, **Eli Lilly**

9 de marzo 2017

12 h

Aula 1, Edif. D. Facultad de Ciencias

CONFERENCIA ISQCH

isqch

Instituto de Síntesis Química y Catálisis Homogénea

 **CSIC**
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS

 **Universidad
Zaragoza**
1542

Colabora:

 **Facultad de Ciencias
Universidad Zaragoza**

Open Innovation Drug Discovery (OIDD): Program Expansion and New Approaches for Collaboration

María Angeles Martínez-Grau, Senior Research Advisor, Eli Lilly

The Lilly OIDD program was created to engage external investigators in a hypothesis-driven approach to early drug discovery. Program participants have the opportunity to contribute to the discovery of novel therapeutics, and benefit by having access to cutting-edge research tools and data that can help them advance their scientific work. The OIDD program is directed to investigators in academic/research institutions and small biotechs. Many of them encountered barriers to evaluate the therapeutic potential of their compounds and OIDD was designed to minimize obstacles by offering:

- In-kind access to a panel of proprietary biological assays in the areas of Diabetes, Oncology, Pain, Neurodegeneration and Immunology, plus certain neglected and tropical diseases in collaboration with global leaders in the area,
- A variety of *in silico* tools to prioritize molecules with desirable drug-like properties,
- Opportunity to prepare compounds remotely in our Automated Synthesis Lab (ASL),
- Opportunity to have chemical samples selected for purchase through an algorithm applied to the molecular descriptor profile.

Affiliation is established at the institution level via a universal agreement that protects participant's intellectual contributions. Once the agreement is signed, investigators at the affiliated institution may create a user account that manage chemical structure selection, sample transfers, and biological data in a secure manner. The OIDD program is supported by a secure web-based interface that protects the confidentiality of proprietary information such as chemical structures. All Lilly-generated data is owned by the participating investigator and/or institution, and results are used to initiate collaboration discussions based on promising results and mutual interest of both parties. Otherwise, the investigator is free to publish and/or use the biological results in grant proposals.

This presentation will describe the scientific rationale behind OIDD, the business model, operational details and metrics illustrating the performance of the program. Detailed information can be found online (<https://openinnovation.lilly.com/>). The website provides details about our offerings, process details, sample logistics, biological screening and user account management. Our universal agreement is also available online. If you have questions, please feel free to contact openinnovation@lilly.com